Centocor seeks paediatric ulcerative colitis indication for Remicade
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech is looking to expand the label for its anti-TNF Remicade (infliximab) to include moderately to severely active ulcerative colitis in paediatric patients who do not adequately respond to conventional therapies. The product is already approved for treating adults with the same condition.